source
- Parkinson's drug pipeline diversifies as firms seek disease-modifying therapiesSeveral pharmaceutical companies are shifting away from the traditional alpha-synuclein antibody strategy and exploring alternative mechanisms to treat Parkinson's disease. AC Immune is highlighted…
- Schrödinger launches Tectora Therapeutics with $55 million Series A to target immunology and inflammationSchrödinger announced the formation of Tectora Therapeutics, a new biotech focused on immune‑mediated diseases, backed by a $55 million Series A financing round. As part of the launch, Schrödinger…